Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.

@article{Delelis2010ImpactOY,
  title={Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.},
  author={Olivier Delelis and Sylvain Thierry and Fr{\'e}d{\'e}ric Subra and Françoise Simon and Isabelle Malet and Chakib Alloui and Sophie Sayon and Vincent Calvez and Eric Deprez and Anne-genevi{\`e}ve Marcelin and Luba Tchertanov and Jean-François Mouscadet},
  journal={Antimicrobial agents and chemotherapy},
  year={2010},
  volume={54 1},
  pages={491-501}
}
Integrase (IN), the HIV-1 enzyme responsible for the integration of the viral genome into the chromosomes of infected cells, is the target of the recently approved antiviral raltegravir (RAL). Despite this drug's activity against viruses resistant to other antiretrovirals, failures of raltegravir therapy were observed, in association with the emergence of resistance due to mutations in the integrase coding region. Two pathways involving primary mutations on residues N155 and Q148 have been… CONTINUE READING

From This Paper

Topics from this paper.
32 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…